V920
Biological
Merck Sharp & Dohme Corporation
Total Payments
$879,314
Transactions
299
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $5,300 | 2 | 0 |
| 2018 | $227,913 | 118 | 0 |
| 2017 | $646,101 | 179 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $879,314 | 299 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase III, Randomized, Placebo-Controlled, Clinical Trial to Study the Safety and immunogenicity of Three Consistency Lots and a High Dose Lot of rVSV-ZEBOV-GP V920 Ebola Vaccine in Healthy Adults | Merck Sharp & Dohme Corporation | $879,314 | 0 |
Top Doctors Receiving Payments for V920
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Miles, TX | $879,314 | 299 |
Ad
Manufacturing Companies
- Merck Sharp & Dohme Corporation $879,314
Product Information
- Type Biological
- Total Payments $879,314
- Total Doctors 0
- Transactions 299
About V920
V920 is a biological associated with $879,314 in payments to 0 healthcare providers, recorded across 299 transactions in the CMS Open Payments database. The primary manufacturer is Merck Sharp & Dohme Corporation.
Payment data is available from 2017 to 2019. In 2019, $5,300 was paid across 2 transactions to 0 doctors.
The most common payment nature for V920 is "Unspecified" ($879,314, 100.0% of total).
V920 is associated with 1 research study, including "A Phase III, Randomized, Placebo-Controlled, Clinical Trial to Study the Safety and immunogenicity of Three Consistency Lots and a High Dose Lot of rVSV-ZEBOV-GP V920 Ebola Vaccine in Healthy Adults" ($879,314).